Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model

View More View Less
  • 1 Departments of Neurological Surgery,
  • 3 Radiology, and
  • 4 Pathology and Cell Biology, and
  • 2 Institute of Comparative Medicine, Columbia University Medical Center, New York, New York; and
  • 5 Division of Neurosurgery, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Intracerebral convection-enhanced delivery (CED) has been limited to short durations due to a reliance on externalized catheters. Preclinical studies investigating topotecan (TPT) CED for glioma have suggested that prolonged infusion improves survival. Internalized pump-catheter systems may facilitate chronic infusion. The authors describe the safety and utility of long-term TPT CED in a porcine model and correlation of drug distribution through coinfusion of gadolinium.

METHODS

Fully internalized CED pump-catheter systems were implanted in 12 pigs. Infusion algorithms featuring variable infusion schedules, flow rates, and concentrations of a mixture of TPT and gadolinium were characterized over increasing intervals from 4 to 32 days. Therapy distribution was measured using gadolinium signal on MRI as a surrogate. A 9-point neurobehavioral scale (NBS) was used to identify side effects.

RESULTS

All animals tolerated infusion without serious adverse events. The average NBS score was 8.99. The average maximum volume of distribution (Vdmax) in chronically infused animals was 11.30 mL and represented 32.73% of the ipsilateral cerebral hemispheric volume. Vdmax was achieved early during infusions and remained relatively stable despite a slight decline as the infusion reached steady state. Novel tissue TPT concentrations measured by liquid chromatography mass spectroscopy correlated with gadolinium signal intensity on MRI (p = 0.0078).

CONCLUSIONS

Prolonged TPT-gadolinium CED via an internalized system is safe and well tolerated and can achieve a large Vdmax, as well as maintain a stable Vd for up to 32 days. Gadolinium provides an identifiable surrogate for measuring drug distribution. Extended CED is potentially a broadly applicable and safe therapeutic option in select patients.

ABBREVIATIONS CED = convection-enhanced delivery; FVd = final volume of distribution; FVi = final volume infused; GBM = glioblastoma; LCMS = liquid chromatography mass spectroscopy; NBS = neurobehavioral scale; TPT = topotecan; Vd = volume of distribution; Vdmax = maximal volume of distribution; Vi = volume of infusion.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Randy S. D’Amico: Columbia University Medical Center, New York, NY. rd2398@cumc.columbia.edu.

ACCOMPANYING EDITORIAL DOI: 10.3171/2019.4.JNS19614.

INCLUDE WHEN CITING Published online August 2, 2019; DOI: 10.3171/2019.3.JNS1963.

P.C. and J.N.B. contributed equally to this work.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

  • 1

    Anderson RC, Kennedy B, Yanes CL, Garvin J, Needle M, Canoll P, : Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr 11:289295, 2013

    • Search Google Scholar
    • Export Citation
  • 2

    Barker FG II, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, : Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709723, 1998

    • Search Google Scholar
    • Export Citation
  • 3

    Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:20762080, 1994

    • Search Google Scholar
    • Export Citation
  • 4

    Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, : Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13:132142, 2011

    • Search Google Scholar
    • Export Citation
  • 5

    Bradac O, Steklacova A, Nebrenska K, Vrana J, de Lacy P, Benes V: Accuracy of VarioGuide frameless stereotactic system against frame-based stereotaxy: prospective, randomized, single-center study. World Neurosurg 104:831840, 2017

    • Search Google Scholar
    • Export Citation
  • 6

    Bruce JN, Falavigna A, Johnson JP, Hall JS, Birch BD, Yoon JT, : Intracerebral clysis in a rat glioma model. Neurosurgery 46:683691, 2000

    • Search Google Scholar
    • Export Citation
  • 7

    Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, : Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69:12721280, 2011

    • Search Google Scholar
    • Export Citation
  • 8

    Burris HA III: Topotecan: incorporating it into the treatment of solid tumors. Oncologist 3:13, 1998

  • 9

    Chow DS, Qi J, Guo X, Miloushev VZ, Iwamoto FM, Bruce JN, : Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme. AJNR Am J Neuroradiol 35:498503, 2014

    • Search Google Scholar
    • Export Citation
  • 10

    Das S, Srikanth M, Kessler JA: Cancer stem cells and glioma. Nat Clin Pract Neurol 4:427435, 2008

  • 11

    Debinski W, Tatter SB: Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 9:15191527, 2009

  • 12

    Desjardins A, Gromeier M, Herndon JE II, Beaubier N, Bolognesi DP, Friedman AH, : Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150161, 2018

    • Search Google Scholar
    • Export Citation
  • 13

    Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, : Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 108:989998, 2008

    • Search Google Scholar
    • Export Citation
  • 14

    Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, McLendon RE, : Topotecan treatment of adults with primary malignant glioma. Cancer 85:11601165, 1999

    • Search Google Scholar
    • Export Citation
  • 15

    Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN: Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47:13911399, 2000

    • Search Google Scholar
    • Export Citation
  • 16

    Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ: Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:865874, 1987

    • Search Google Scholar
    • Export Citation
  • 17

    Ksendzovsky A, Walbridge S, Saunders RC, Asthagiri AR, Heiss JD, Lonser RR: Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurg 117:197203, 2012

    • Search Google Scholar
    • Export Citation
  • 18

    Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, : Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12:871881, 2010

    • Search Google Scholar
    • Export Citation
  • 19

    Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, : Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837844, 2007

    • Search Google Scholar
    • Export Citation
  • 20

    Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, : Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472479, 2004

    • Search Google Scholar
    • Export Citation
  • 21

    Lonser RR, Sarntinoranont M, Morrison PF, Oldfield EH: Convection-enhanced delivery to the central nervous system. J Neurosurg 122:697706, 2015

    • Search Google Scholar
    • Export Citation
  • 22

    Lopez KA, Tannenbaum AM, Assanah MC, Linskey K, Yun J, Kangarlu A, : Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res 71:39633971, 2011

    • Search Google Scholar
    • Export Citation
  • 23

    Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T, Nagao S: Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 53:97103, 1993

    • Search Google Scholar
    • Export Citation
  • 24

    Mehta AM, Sonabend AM, Bruce JN: Convection-enhanced delivery. Neurotherapeutics 14:358371, 2017

  • 25

    Midulla PS, Gandsas A, Sadeghi AM, Mezrow CK, Yerlioglu ME, Wang W, : Comparison of retrograde cerebral perfusion to antegrade cerebral perfusion and hypothermic circulatory arrest in a chronic porcine model. J Card Surg 9:560575, 1994

    • Search Google Scholar
    • Export Citation
  • 26

    Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schröder E, : Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 101:267277, 2011

    • Search Google Scholar
    • Export Citation
  • 27

    Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, : Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267275, 2005

    • Search Google Scholar
    • Export Citation
  • 28

    Raghavan R, Brady ML, Rodríguez-Ponce MI, Hartlep A, Pedain C, Sampson JH: Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 20(4):E12, 2006

    • Search Google Scholar
    • Export Citation
  • 29

    Raghavan R, Brady ML, Sampson JH: Delivering therapy to target: improving the odds for successful drug development. Ther Deliv 7:457481, 2016

    • Search Google Scholar
    • Export Citation
  • 30

    Rainov NG, Gorbatyuk K, Heidecke V: Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 3:29, 2008

    • Search Google Scholar
    • Export Citation
  • 31

    Rogawski MA: Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 6:344351, 2009

  • 32

    Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, : Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:2735, 2003

    • Search Google Scholar
    • Export Citation
  • 33

    Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, : Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113:301309, 2010

    • Search Google Scholar
    • Export Citation
  • 34

    Sampson JH, Raghavan R, Brady M, Friedman AH, Bigner D: Convection-enhanced delivery. J Neurosurg 115:463466, 2011

  • 35

    Sonabend AM, Stuart RM, Yun J, Yanagihara T, Mohajed H, Dashnaw S, : Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol 13:886893, 2011

    • Search Google Scholar
    • Export Citation
  • 36

    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987996, 2005

    • Search Google Scholar
    • Export Citation
  • 37

    Szerlip NJ, Walbridge S, Yang L, Morrison PF, Degen JW, Jarrell ST, : Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 107:560567, 2007

    • Search Google Scholar
    • Export Citation
  • 38

    Vogelbaum MA: Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol 83:97109, 2007

    • Search Google Scholar
    • Export Citation
  • 39

    Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, : Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61:10311038, 2007

    • Search Google Scholar
    • Export Citation
  • 40

    Yun J, Rothrock RJ, Canoll P, Bruce JN: Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv 2013:107573, 2013

    • Search Google Scholar
    • Export Citation
  • 41

    Zhao H, Traganos F, Darzynkiewicz Z: Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Cytometry A 73:480489, 2008

    • Search Google Scholar
    • Export Citation
  • 42

    Zhou Z, Singh R, Souweidane MM: Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol 15:116128, 2017

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 141 141 141
Full Text Views 50 50 50
PDF Downloads 26 26 26
EPUB Downloads 0 0 0